Direct Costs of RSV Cases in Hospitalized Patients (Aged ≥60 Years) Identified From 2010-2020 in a Retrospective Study in Valladolid, Spain

Speaker(s)

Sanz-Muñoz I1, Sanchez-Martinez J2, Toquero-Asensio M2, Iglesia-Aparicio R2, Martín-Toribio A2, López-Gonzalo C2, Rodríguez-Crespo C2, Sierra-Martínez L3, Pérez-Pertejo JF4, Nuñez-Villareal G4, Rodríguez-García R4, Fernández-González MR2, Martín-Del barco OH4, Alarcia-Santana I4, Gómez-Muñoz A4, Alonso-Estomba C4, Asenjo-Martín A4, Renedo-Velasco G4, Moral-Blanco M4, Muñoz-Hernández JG4, Vega-Hernández O4, Rodriguez-Calleja M4, Gonzalo-Fernández MDM4, Reeves RM5, Mahmood A6, Izquierdo-Diaz L7, Hernán-García C2, Domínguez-Gil M2, Rojo-Rello S2, Fernández-Espinilla V2, Castrodeza-Sanz J2, Eiros JM2
1National Influenza Centre, Valladolid, Spain, 2National Influenza Centre, Valladolid, Valladolid, Spain, 3Atención Primaria, Área de Salud Este de Valladolid, Valladolid, VA, Spain, 4Atención Primaria, Área de Salud Este de Valladolid, Valladolid, Valladolid, Spain, 5GSK, London, London, UK, 6GSK, Brussels, Brussels, Belgium, 7GSK, Madrid, Madrid, Spain

OBJECTIVES: Respiratory Syncytial Virus (RSV) hospitalizations represents a significant burden of disease for which the exact direct healthcare cost is unknown. The aim of this analysis was to estimate direct costs of hospitalized laboratory-confirmed RSV cases in Valladolid, Spain.

METHODS: Retrospective study including hospitalized patients with RSV lab-confirmed infection in two hospitals in Valladolid, covering around 200,000 people ³60 years of age during 10 years (1/4/2010–31/3/2020). Direct healthcare costs were estimated based on duration of hospitalization, Intensive Care Unit (ICU) stay, subsequent hospitalization related visits to primary care (PC) and specialists, subsequent emergency department visits and hospital readmissions due to their illness. A descriptive analysis and an analysis of the average costs per resource was performed. In addition, the total cost of health care over the 2010-2020 period was estimated.

RESULTS: A total of 591 patients hospitalized were included. Of them, 22.2% required hospital readmission, 27.0% required visits to the specialist, 20.8% required visits to PC and 6.8% required ICU admission. The mean length of stay was 11.5 (Standard Deviation,SD:12.5) days for hospitalization, 12.2 days (SD:11.9) days for ICU admission and 9.9 (SD:12.0) days for rehospitalization, resulting in a mean of €5,759.0 (SD:6,283.4), €15,748.6 (SD:15,503.3) and €4,943.5 (SD:5,817.2) per stay respectively. The total cost of laboratory-confirmed RSV associated to hospitalization, ICU and re-hospitalization in our study population during this period was €5,017,158.16 (mean per season: €501,715.8[SD:578,297.6]).

CONCLUSIONS: This analysis in adults ³60 years in the province of Valladolid in Spain suggests that the annual mean cost of laboratory-confirmed RSV in hospitalized patients is estimated to be approximately €500,000 per season. Hospitalization therefore has a substantial impact on the direct economic burden of RSV, especially since the current study is expected to underestimate the total number of RSV cases (and therefore cost) as it only includes laboratory-confirmed RSV cases identified per routine patient care.

Code

EE588

Topic

Economic Evaluation

Disease

Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)